Eradication of large established tumors in mice by combination immunotherapy that engages innate and adaptive immune responses

Checkpoint blockade with antibodies specific for cytotoxic T lymphocyte-associated protein (CTLA)-4 or programmed cell death 1 (PDCD1; also known as PD-1) elicits durable tumor regression in metastatic cancer, but these dramatic responses are confined to a minority of patients. This suboptimal outco...

Full description

Bibliographic Details
Main Authors: Cochran, Jennifer R (Author), Moynihan, Kelly Dare (Contributor), Opel, Cary Francis (Contributor), Szeto, Gregory (Contributor), Tzeng, Alice (Contributor), Zhu, Eric Franklin (Contributor), Engreitz, Jesse Michael (Contributor), Williams, Robert T. (Contributor), Rakhra, Kavya (Contributor), Zhang, Michael H (Contributor), Rothschilds, Adrienne Marie (Contributor), Kumari, Sudha (Contributor), Kelly, Ryan Lewis (Contributor), Kwan, Byron Hua (Contributor), Abraham, Wuhbet (Contributor), Hu, Kevin (Contributor), Mehta, Naveen (Contributor), Kauke, Monique Jacqueline (Contributor), Suh, Heikyung (Contributor), Lauffenburger, Douglas A (Contributor), Wittrup, Karl Dane (Contributor), Irvine, Darrell J (Contributor)
Other Authors: Broad Institute of MIT and Harvard (Contributor), Massachusetts Institute of Technology. Department of Biological Engineering (Contributor), Massachusetts Institute of Technology. Department of Biology (Contributor), Massachusetts Institute of Technology. Department of Chemical Engineering (Contributor), Massachusetts Institute of Technology. Department of Materials Science and Engineering (Contributor), Ragon Institute of MGH, MIT and Harvard (Contributor), Koch Institute for Integrative Cancer Research at MIT (Contributor)
Format: Article
Language:English
Published: Nature Publishing Group, 2017-06-13T18:03:16Z.
Subjects:
Online Access:Get fulltext